N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the tolerance of different doses and to look at tumour regression.
Read the full summary of findings here.
